Infliximab is effective in the treatment of ulcerative colitis with dermatomyositis: A case report

Abstract

BACKGROUND

Joint, skin, oral cavity, and eye lesions are the most common extraintestinal manifestations of ulcerative colitis that can occur before or after its onset. The cases of ulcerative colitis with dermatomyositis (DM) are rare. In this study, we report a rare case of ulcerative colitis with DM that was effectively treated with infliximab.

CASE SUMMARY

The patient was a 57-year-old female with a 2-year history of DM. The patient was admitted to hospital with abdominal pain, diarrhea, and blood in stool lasting for more than 2 mo. Colonoscopy revealed multiple erosions and ulcers in the entire colon and rectum. Pathological sections showed chronic inflammatory cell infiltration, especially neutrophil infiltration, in the colonic mucosa; therefore, the patient was diagnosed with ulcerative colitis. Preparations of 5-aminosalicylic acid was added to her treatment based on the original treatment for DM, but its effect was unsatisfactory. The patient’s discomfort was relieved after infliximab treatment.

CONCLUSION

Infliximab can improve DM in the treatment of ulcerative colitis. Specialists need to raise awareness about patients with inflammatory bowel disease who have rare extraintestinal manifestations.

Key Words: Ulcerative colitis, Dermatomyositis, Extraintestinal manifestation, Infliximab, Mesalazine, Case report

Core Tip: Few cases of ulcerative colitis have dermatomyositis (DM) as complication. DM may be a less frequent extraintestinal manifestation of ulcerative colitis. Infliximab is effective in the treatment of ulcerative colitis in patients with autoimmune disease or poor hormone response.

INTRODUCTION

Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD) characterized by abdominal pain, diarrhea, and bloody mucus defecation and usually occurs in the rectum and colonic mucosa[1]. UC, as a systemic inflammatory disease, can have a variety of extraintestinal manifestations (EIMs) with an incidence of more than 20% in some countries[2,3]. The EIMs of IBD have two types. The first type is associated with the severity of IBD and includes oral aphthous ulcers and erythema nodosum. The second type, which includes ankylosing spondylitis and uveitis, is independent from the intestinal inflammation of IBD and is associated with autoimmune diseases[4]. IBD also has rare myopathy-type EIMs, such as orbital myositis[5]. Only a few cases of IBD with dermatomyositis (DM) are reported on PubMed[6,7].

DM is an inflammatory disease of the skin and muscle that is characterized by the presence of specific antibodies and elevated creatine kinase[8]. Muscle biopsy reveals atrophy of the muscle tract[9]. This paper reports a case of UC with DM treated by infliximab and reviews its pathogenesis and treatment. We hope this report will provide recommendations for the treatment of IBD with rare EIMs.

CASE PRESENTATION

Chief complaints

The patient was a 57-year-old woman whose chief complaint was abdominal pain, diarrhea, and bloody mucus stool for more than 2 mo.

History of present illness

Diarrhea with bloody mucus stool occurred suddenly more than ten times a day since early August 2018. The patient also had periumbilical pain, which can be relieved after defecation. She did not have fever, cough, chest tightness, or other discomfort.

History of past illness

The patient was hospitalized in early June 2016 for eyelid edema, limb weakness, and swallowing difficulties. She had a series of typical clinical symptoms of DM, such as Gottron’s papules in the extensor surfaces of the metacarpophalangeal joints, V-neck sign, facial erythema, and periorbital edema (Figure 1). Electromyography showed myogenic damage. Muscle biopsy pathology (Figure 2) and magnetic resonance imaging (Figure 3) supported myositis. The patient was initially given prednisone [50 mg every day (qd) orally (po)] and methotrexate (15 mg once a week po). She did not stop taking the glucocorticoid and methotrexate for a long time after discharge, during which she added immunosuppressive drugs, such as cyclosporine and hydroxychloroquine, in combination and adjusted the dosage of hormones because of her unstable condition. The patient continued to suffer from limb weakness and dysphagia in early August 2018, but no new rash or edema appeared throughout the body when she was taking prednisone (10 mg qd po), methotrexate (10 mg once a week po), and cyclosporine [50 mg twice a day (bid) po]. She had a history of hypertension and depression and had undergone appendectomy.

Figure 1 Periorbital and facial edema upon the patient’s diagnosis of dermatomyositis in 2016.

Figure 2 Pathology of left upper arm muscle. Transverse striations of muscle fibers can be seen. Atrophy and fibrosis were not observed. Local intermuscular vascular dilatation and infiltration with a small amount of lymphocytes were noted.

Figure 3 Plain magnetic resonance imaging scan of the middle and upper parts of the right thigh. A patchy higher signal can be seen in the fat-inhibited part of the T2-weighted images of multiple muscle tissues in buttocks and middle and upper thigh with unclear boundary and uneven signal.

Personal and family history

The patient did not have a history of smoking or drinking.

Physical examination

The patient was 160 cm tall, weighed 45 kg, and had a body mass index of 17.58. Blotchy pigmentation was present on the neck, both legs, and hips. She had abdominal tenderness but not rebound pain. Her limbs and neck muscles also had tenderness. Her distal muscle strength was level 4, her proximal muscle strength was level 3, and her muscle tone was normal.

Laboratory examinations

The result of routine blood examination was as follows: White blood cell count, 5.03 × 10⁹/L; red blood cell count, 2.42 × 10¹²/L; and hemoglobin, 70.70 g/L. Routine stool examination showed positive occult blood with red and white blood cells in the stool. Liver function showed that her albumin decreased to 32.60 g/L. D-dimer was 742 ng/mL. The autoantibody test results were as follows: antinuclear antibody (+), anticentromere antibody (+), anti-Ro52 antibody (+), and anticentromere protein B antibody (+). Immunofluorescence staining indicated a centromeric-type disease (1:320). Parasites and bacteria were not found in the feces. Cardiac enzymes, tuberculosis antibody, T-spot test, cytomegalovirus DNA and antibodies, Epstein-Barr virus antibodies, and tumor markers were normal.

Imaging examinations

Colonoscopy showed multiple hyperemia, erosion, and ulcers in the whole colon and rectum. The ulcer was approximately 0.3-0.6 cm and was accompanied by yellow and white moss-like structures and edema of the surrounding mucosa. Part of the ileum had hyperemia and erosion. Multiple broad basal and pedicled polyps with a red surface and a size of 0.3-0.7 cm was found in the ileocecal region (Figure 4).

Figure 4 Colonoscopic presentation of ulcerative colitis.

Pathological results showed a moderate chronic inflammation of the transverse colon mucosa accompanied by neutrophil infiltration and appendage as the ulcer changed (Figure 5).

Figure 5 Intestinal mucosal biopsy at the time of diagnosis of ulcerative colitis.

Computed tomography enterography showed that the wall of the splenic curvature, descending colon, sigmoid colon, and rectum were slightly thickened and the colonic pouch became shallow, part of which was like sausage. These characteristics turned out to be UC (Figure 6).

Figure 6 Abdominal computed tomography at the time of diagnosis of ulcerative colitis.

MULTIDISCIPLINARY EXPERT CONSULTATION

Zhan-Rui Chen, BM, Associate Chief Physician of Rheumatology and Immunology.

Yun Pei, BM, Associate Chief Physician of Radiology.

Zu-Yun Li, Master of Pathology and Pathophysiology, Associate Chief Physician, and Associate Professor of Pathology.

Jun-Lin Liang, MD, Chief Physician, and Professor of Colorectal and Anal Surgery.

Yong-Sheng Zhang, MM, Associate Chief Physician of Nutrition.

Xiao-Ping Lv, MM, Chief Physician, and Professor of Gastroenterology.

FINAL DIAGNOSIS

After multidisciplinary consultation in our hospital, the patient was diagnosed with: (1) UC (type of first episode, extensive colonic type, moderate, active stage) with a Mayo score of 9[10-12]; (2) DM; (3) Multiple colon polyps; (4) Coronary atherosclerotic heart disease; and (5) Hypertension.

TREATMENT

Mesalazine was temporarily added to treat intestinal symptoms because the patient was already taking glucocorticoids and immunosuppressants. We gave the patient prednisone (10 mg qd po), methotrexate (10 mg once a week po), cyclosporine (50 mg bid po), mesalazine (2 g bid po), and pivionium bromide (50 mg thrice a day po) as well as early symptomatic treatment, such as albumin supplementation and the regulation of intestinal flora, from October 18, 2018 to November 1, 2018. However, the digestive tract symptoms did not improve. We consulted the expert opinions of the rheumatology department and finally gave the patient gamma globulin [5 g qd for 3 d via intravenous (IV) drip] combined with prednisone acetate (5 mg qd for 10 d po). On November 6, 2018, we gave infliximab (5 mg/kg via IV drip) treatment supplemented by mesalazine (2 g bid po). The patient occasionally experienced abdominal pain, did not have diarrhea, and was able to defecate formed stool once a day after the first injection of infliximab. Thus, the patient was discharged. The patient was instructed to take a daily dose of mesalazine (2 g bid po) at home, and she returned to the hospital regularly for infliximab treatment at weeks 2 and 6 and then every 8 wk after the fourth treatment.

OUTCOME AND FOLLOW-UP

At home, the patient occasionally experienced abdominal pain but did not have diarrhea and was able to excrete formed stool once a day. Muscle pain and weakness in the extremities were remarkably relieved, and the skin rash around the eyes and the back of the hand darkened in color and reduced in size day by day. She gained 15 kg with an increase in body mass index and could walk independently by the fourth injection of infliximab. She also had a good control of depression (Figure 7). Her symptoms disappeared during the fourth treatment with infliximab. Abdominal computed tomography showed that the wall of the colon and rectum was slightly thickened compared to before (Figure 8). Colonoscopy re-examination showed that the mucosa of the whole colon and rectum were slightly edematous and less smooth with the formation of scattered ulcer scars and the presence of a little patchy mucosal erosion. Vascular texture was coarse and messy. The ulcer also improved and disappeared (Figure 9). The updated diagnosis was UC (extensive colonic type, mild, remission) with a Mayo score of 2[11,12].

Figure 7 Patient status after treatment with infliximab. The patient recovered her muscle strength in proximal extremities and could freely move without needing a wheelchair.

Figure 8 Computed tomography re-examination of the small intestines after the fourth infliximab treatment.

Figure 9 Colonoscopy re-examination after the fourth infliximab treatment.

DISCUSSION

The most common digestive tract discomfort in adult DM is dysphagia, whereas gastrointestinal involvement is relatively rare[13,14]. Gastrointestinal symptoms in patients with DM may be caused by mild gastrointestinal vasculitis and the involvement of the smooth muscles of the intestines[15]. Kidambi et al[14] found that 79.1% of patients with DM who underwent colonoscopy because of abdominal pain and diarrhea had no organic lesions in the gastrointestinal tract, whereas the rest were mostly complicated by rare intestinal adenomas. Therefore, the possibility of DM-associated enteritis is very small.

About a quarter of patients will develop EIMs prior to IBD onset, and the rest will develop parenteral manifestations after IBD diagnosis[4]. IBD can be associated with DM[6,7]. The results of Tseng et al[16] showed that the cumulative incidence of DM in patients with UC is higher than that of the control group, and UC is positively correlated with DM. We suspect that their correlation is caused by their similar mechanisms. Autoimmune diseases, such as DM, and autoinflammatory disease, such as IBD, are at the opposite ends of the same disease spectrum[17]. DM and UC have imbalances of Th17 and Treg cytokines, in which Th17 is increased and Treg is decreased[18,19]. A large-scale retrospective study on the combination of IBD and DM locally or abroad has not been conducted yet because of the low incidence of these diseases. Thus, the connection and mechanism of the two diseases remain unexplored.

The diagnosis of DM in this patient was definite. The patient still had skin pigmentation after long-term treatment with prednisone, methotrexate, and cyclosporine, but the rash and muscle strength were remarkably improved; therefore, the patient’s DM was stable. Vasculitis can cause gastrointestinal diseases, but the patient had no other symptoms of vasculitis. The result of vasculitis-related immunological examination was normal. Small intestinal computed tomography enterography showed no characteristic manifestations of ischemic enterocolitis, such as comb sign or the target sign of mesenteric vessels[20]. The rheumatology expert thought that the evidence of vasculitis was insufficient. We diagnosed the patient with UC rather than other DM-related intestinal disease based on the results of the colonoscopy and pathological biopsy. DM and IBD have similar but different drug treatments. Therefore, we considered whether to use DM-based or UC-based treatments. The symptoms of patients with DM and IBD are remarkably improved by hormones and 5-aminosalicylic acid[6,7]. However, the patient’s condition was not improved by mesalazine, which is a DM-based treatment. The patient’s condition 2 years prior to the onset of intestinal symptoms was poorly controlled by multiple hormonal and immunosuppressive drugs. Therefore, we presumed that the patient had a negative reaction to hormones. In addition, this patient had extensive intestinal lesions, low albumin, and anemia, which indicate severe ulcerative colitis[21]. Therefore, we gave the patient an early conversion treatment of infliximab to control intestinal inflammation.

Infliximab is a chimeric monoclonal antibody against tumor necrosis factor-α. It is a combination of human and mouse proteins. It can induce the production of regulatory macrophages and the apoptosis of proinflammatory T helper cells, inhibit growth factors, and downregulate the proinflammatory activity of neutrophils[22,23]. Several studies have reported the efficacy of infliximab in IBD, which is used for patients with moderate to severe IBD who are unresponsive to hormones and immunosuppressive agents or have serious adverse reactions to these drugs[24]; therefore, infliximab can benefit patients with the EIMs of IBD, such as erythema nodosum, ankylosing spondylitis, and pyoderma[25]. Common adverse reactions caused by infliximab include acute infusion reactions, such as skin rashes, headaches, flushing, hypotension, and other allergic reactions. Given that infliximab also increases the risk of malignant tumors, neurological diseases, and infections and exerts other adverse effects, such as liver, blood system, heart, and other system damage, patients need to be screened for tuberculosis and hepatitis B virus infection, advanced heart failure (New York Heart Association III or IV Grade), and neurological diseases before treatment with this drug[26,27].

Patients with IBD receive intravenous injections of infliximab every 8 wk at 0, 2, 6, and thereafter at a dose of 5 mg/kg in accordance with drug safety, effectiveness, and economy[12]. Although researchers believe that anti-tumor necrosis factor-α can also be used for DM, few have studied the effects of infliximab on DM. Some case reports indicated that infliximab is beneficial for the treatment of DM with interstitial lung diseases[28]. A randomized double-blind controlled study showed that infliximab can improve muscle strength in patients with polymyositis and DM[29]. We gave the patient an IV injection of gamma globulin as an adjuvant therapy before the first infliximab treatment to control disease progression. Gamma globulin can be used in patients with IBD[30] and refractory DM who cannot respond to hormones and immunosuppressive drugs effectively[31]. The patient remained stable in the follow-up treatment with infliximab and mesalazine alone. The effective control of UC is conducive to the improvement of EIMs, such as DM.

CONCLUSION

Immune-mediated diseases can involve multiple organs and cause many difficulties for specialists in differential diagnosis. Rare systemic association should be considered in the diagnosis and treatment of such diseases when symptoms are not related or the condition cannot be improved under conventional treatment. The use of biological agents is a new approach in the treatment of these rare diseases.